These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11604470)

  • 41. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway.
    Ramaswamy S; Nakamura N; Vazquez F; Batt DB; Perera S; Roberts TM; Sellers WR
    Proc Natl Acad Sci U S A; 1999 Mar; 96(5):2110-5. PubMed ID: 10051603
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Loss of PTEN facilitates HIF-1-mediated gene expression.
    Zundel W; Schindler C; Haas-Kogan D; Koong A; Kaper F; Chen E; Gottschalk AR; Ryan HE; Johnson RS; Jefferson AB; Stokoe D; Giaccia AJ
    Genes Dev; 2000 Feb; 14(4):391-6. PubMed ID: 10691731
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein.
    Paramio JM; Navarro M; Segrelles C; Gómez-Casero E; Jorcano JL
    Oncogene; 1999 Dec; 18(52):7462-8. PubMed ID: 10602505
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells.
    Kandasamy K; Srivastava RK
    Cancer Res; 2002 Sep; 62(17):4929-37. PubMed ID: 12208743
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway.
    Zhang J; Choi Y; Mavromatis B; Lichtenstein A; Li W
    Oncogene; 2003 Sep; 22(40):6289-95. PubMed ID: 13679867
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [mTOR, the mammalian target of rapamycin].
    Julien LA; Roux PP
    Med Sci (Paris); 2010 Dec; 26(12):1056-60. PubMed ID: 21187044
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic potential of target of rapamycin inhibitors.
    Easton JB; Houghton PJ
    Expert Opin Ther Targets; 2004 Dec; 8(6):551-64. PubMed ID: 15584862
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
    Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
    Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Trypanosoma cruzi trans-sialidase: a potent and specific survival factor for human Schwann cells by means of phosphatidylinositol 3-kinase/Akt signaling.
    Chuenkova MV; Furnari FB; Cavenee WK; Pereira MA
    Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9936-41. PubMed ID: 11481434
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells.
    She QB; Solit DB; Ye Q; O'Reilly KE; Lobo J; Rosen N
    Cancer Cell; 2005 Oct; 8(4):287-97. PubMed ID: 16226704
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Putting the rap on Akt.
    Thompson JE; Thompson CB
    J Clin Oncol; 2004 Oct; 22(20):4217-26. PubMed ID: 15483033
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation.
    Liu JL; Sheng X; Hortobagyi ZK; Mao Z; Gallick GE; Yung WK
    Mol Cell Biol; 2005 Jul; 25(14):6211-24. PubMed ID: 15988030
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
    Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
    Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biochemical differences between SUDHL-1 and KARPAS 299 cells derived from t(2;5)-positive anaplastic large cell lymphoma are responsible for the different sensitivity to the antiproliferative effect of p27(Kip1).
    Turturro F; Frist AY; Arnold MD; Seth P; Pulford K
    Oncogene; 2001 Jul; 20(33):4466-75. PubMed ID: 11494142
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth.
    Altomare DA; You H; Xiao GH; Ramos-Nino ME; Skele KL; De Rienzo A; Jhanwar SC; Mossman BT; Kane AB; Testa JR
    Oncogene; 2005 Sep; 24(40):6080-9. PubMed ID: 15897870
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways.
    Gu J; Tamura M; Yamada KM
    J Cell Biol; 1998 Nov; 143(5):1375-83. PubMed ID: 9832564
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
    Panwalkar A; Verstovsek S; Giles FJ
    Cancer; 2004 Feb; 100(4):657-66. PubMed ID: 14770419
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pleiotropic effects of statins: acutely good, but chronically bad?
    Schulz R
    J Am Coll Cardiol; 2005 Apr; 45(8):1292-4. PubMed ID: 15837264
    [No Abstract]   [Full Text] [Related]  

  • 59. Introduction: multifaceted roles of lipids and their catabolites in immune cell signaling.
    Ott VL; Cambier JC
    Semin Immunol; 2002 Feb; 14(1):1-6. PubMed ID: 11884225
    [No Abstract]   [Full Text] [Related]  

  • 60. Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN/akt-dependent and -independent pathways.
    Liu W; Asa SL; Fantus IG; Walfish PG; Ezzat S
    Am J Pathol; 2002 Feb; 160(2):511-9. PubMed ID: 11839571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.